267 related articles for article (PubMed ID: 24603336)
1. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
Xu J; Wang J; Hu Y; Qian J; Xu B; Chen H; Zou W; Fang JY
Cell Death Dis; 2014 Mar; 5(3):e1108. PubMed ID: 24603336
[TBL] [Abstract][Full Text] [Related]
2. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
3. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
7. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
[TBL] [Abstract][Full Text] [Related]
8. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
Zhang Y; Hu Y; Fang JY; Xu J
Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
11. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
12. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
13. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.
Martinez-Rivera M; Siddik ZH
Biochem Pharmacol; 2012 Apr; 83(8):1049-62. PubMed ID: 22227014
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
Dong P; Xu Z; Jia N; Li D; Feng Y
Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
[TBL] [Abstract][Full Text] [Related]
15. Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness.
Olszewski MB; Pruszko M; Snaar-Jagalska E; Zylicz A; Zylicz M
Int J Oncol; 2019 Apr; 54(4):1168-1182. PubMed ID: 30968154
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
17. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
19. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.
Vaughan CA; Singh S; Windle B; Sankala HM; Graves PR; Andrew Yeudall W; Deb SP; Deb S
Arch Biochem Biophys; 2012 Feb; 518(1):79-88. PubMed ID: 22198284
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
